New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
Subscribe To Our Newsletter & Stay Updated
